Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 Code History

Introduction of Eculizumab into Central Vein, Percutaneous Approach, New Technology Group 6 Code History

Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10 Code History

Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7 Code History

Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6 Code History

Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3 Code History

Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7 Code History

Introduction of Cefiderocol Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6 Code History

Introduction of Odronextamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10 Code History

Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8 Code History